Drug Patents owned by Biocryst
1. Drug name - ORLADEYO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US10329260 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US10125102 | BIOCRYST | Human plasma kallikrein inhibitors |
Apr, 2035
(12 years from now) | |
| US10662160 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(17 years from now) | |
| CN106257976B | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| CN106257976A | BIOCRYST | Human Plasma Kallikrein Inhibitor |
Mar, 2035
(12 years from now) | |
| EP3113772A4 | BIOCRYST | Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| EP3113772A1 | BIOCRYST | Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| EP3113772B8 | BIOCRYST | Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| EP3113772B1 | BIOCRYST | Trifluoromethyl Substituted Pyrazoles As Human Plasma Kallikrein Inhibitors |
Mar, 2035
(12 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10689346 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US11230530 | BIOCRYST | Human plasma kallikrein inhibitors |
Mar, 2035
(12 years from now) | |
| US11117867 | BIOCRYST | Crystalline salts of a plasma kallikrein inhibitor |
Nov, 2039
(17 years from now) | |
Drugs and Companies using BEROTRALSTAT HYDROCHLORIDE ingredient
Treatment: Prophylaxis to prevent attacks of hereditary angiodema (hae) in adults and pediatric patients 12 years of age and older; Prophylaxis to prevent attacks of hereditary angioedema (hae) in adults and pediatric patients 12 years of age and older
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 110MG BASE | CAPSULE;ORAL | Prescription |
| EQ 150MG BASE | CAPSULE;ORAL | Prescription |
2. Drug name - RAPIVAB
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US6562861 | BIOCRYST | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Dec, 2023
(1 year, 2 months from now) | |
| CN1282316A | BIOCRYST | Substituted Cyclopentane And Cyclopentene Compound Useful As Neuraminidase Inhibitors |
Jun, 2005
(17 years ago) | |
| EP1040094B1 | BIOCRYST | Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors |
Dec, 2018
(3 years ago) | |
| EP1040094B9 | BIOCRYST | Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors |
Dec, 2018
(3 years ago) | |
| EP1040094A4 | BIOCRYST | Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors |
Dec, 2018
(3 years ago) | |
| EP1040094A1 | BIOCRYST | Substituted Cyclopentane And Cyclopentene Compounds Useful As Neuraminidase Inhibitors |
Dec, 2018
(3 years ago) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10391075 | BIOCRYST | Antiviral treatments |
Feb, 2027
(4 years from now) | |
| US8778997 | BIOCRYST | Antiviral treatments |
May, 2027
(4 years from now) | |
Drugs and Companies using PERAMIVIR ingredient
Treatment: Treatment of acute uncomplicated influenza in patients 2 years and older; treatment of acute uncomplicated influenza in patients 6 months and older; Treatment of acute uncomplicated influenza in patients 2 years and older; treatment of acute uncomplicated influenza in adults; treatment of acute uncomplicated influenza in patients 6 months and older
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 200MG/20ML (10MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.